Tyrosine News and Research RSS Feed - Tyrosine News and Research

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell. [More]
People who eat high protein foods have lower blood pressure and arterial stiffness

People who eat high protein foods have lower blood pressure and arterial stiffness

Eating foods rich in amino acids could be as good for your heart as stopping smoking or getting more exercise - according to new research from the University of East Anglia. [More]
IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI). [More]
caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

caprotec bioanalytics GmbH announced today that the United States Patent Office has issued patent No. US9,034,789 covering its revolutionary Capture Compound Mass Spectrometry (CCMS) technology. [More]
CML survey reveals patient TKI adherence, disease anxiety

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness. [More]
TKI outcomes ‘unfavourable’ in young CML patients

TKI outcomes ‘unfavourable’ in young CML patients

Adolescent and young adult patients with chronic myeloid leukaemia may have an unfavourable outcome on tyrosine kinase inhibitor therapy compared with their older counterparts, suggests a study of Japanese patients. [More]
HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Allogeneic haematopoietic stem cell transplantation can be considered for chronic- and accelerated-phase chronic myeloid leukaemia patients with prior exposure to second-generation tyrosine kinase inhibitors, say Polish researchers. [More]
HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Allogeneic haematopoietic stem cell transplantation can be considered for chronic- and accelerated-phase chronic myeloid leukaemia patients with prior exposure to second-generation tyrosine kinase inhibitors, say Polish researchers. [More]
CML survey reveals patient TKI adherence, disease anxiety

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness. [More]

TKI outcomes ‘unfavourable’ in young CML patients

Adolescent and young adult patients with chronic myeloid leukaemia may have an unfavourable outcome on tyrosine kinase inhibitor therapy compared with their older counterparts, suggests a study of Japanese patients. [More]
Vascular side effects prevent first-line ponatinib use in chronic phase CML

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment. [More]

Hedgehog blockade promising in myeloid malignancies

Phase I trial results published in The Lancet Haematology show that the hedgehog signalling pathway antagonist PF-04449913 is tolerable and has activity in patients with haematological cancers. [More]
PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib). [More]
New tool combines drugs to target kinase dependency in cancer

New tool combines drugs to target kinase dependency in cancer

Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond their intended target alone. The result is threefold: sometimes a drug is prescribed to treat a target that proves to be irrelevant to the disease, sometimes an existing drug could be used to treat a cancer for which there is no approved targeted therapy, and sometimes a combination of targeted treatments could be used to simultaneously silence more than one genetic cause of a patient's cancer. [More]
Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition. [More]
Researchers decode molecular mechanism of fish toxin that has potential to treat cancer

Researchers decode molecular mechanism of fish toxin that has potential to treat cancer

Pathogenic bacteria develop killer machines that work very specifically and highly efficiently. Scientists from the University of Freiburg have solved the molecular mechanism of a fish toxin that could be used in the future as a medication to treat cancer. The scientists have now published their research in the journal Nature Communications. [More]
Bosutinib resistance linked to ABCB1 transporter

Bosutinib resistance linked to ABCB1 transporter

Resistance to the tyrosine kinase inhibitor bosutinib may be mediated by overexpression of the efflux transporter ABCB1, scientists suggest. [More]
Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

Chronic myeloid leukaemia patients with rare BCR-ABL fusions may be missed by quantitative polymerase chain reaction, research suggests. [More]
New, nontoxic surgical glue helps heal wounds without scar or inflammation

New, nontoxic surgical glue helps heal wounds without scar or inflammation

One of the most basic yet important surgical skills to keep a patient alive and intact may be closing wounds. It seems that doctors will now get the job done with more ease thanks to new, nontoxic surgical glue that instantly seals a bleeding wound and helps it heal without a scar or inflammation. [More]
Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Advertisement
Advertisement